|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Role of Dusp6 Phosphatase as a Tumor Suppressor in Non-Small Cell Lung Cancer.
|
31027181 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Hinokitiol rapidly induced ERK phosphorylation followed by a sustained dephosphorylation, which accompanied with an increase in expression of tumor suppressor MKP-3 (mitogen-activated protein kinase phosphatase-3).
|
30684529 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Twenty-five fresh pre- and post-dose tumor sample pairs were collected for biomarker analyses, which included assessment of binimetinib on MEK/MAPK signaling by pharmacodynamic analysis of pERK and DUSP6 expression in pre- vs post-dose tumor biopsies; identification of pERK and DUSP6 expression/efficacy correlations; assessment of baseline tumor molecular status; and exploration of potential predictive biomarkers of efficacy of binimetinib.
|
30956763 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
DUSP1 and DUSP6 are expressed in NF1-deleted tumors.
|
30936125 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In addition, Dusp6 gene deletion markedly enhanced tumor load in Apc <sup>Min/+</sup> mice.
|
30273442 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Here, we demonstrate the broad applicability of this recombination-based method and we proved its potential to identify new drug targets via the identification of the tumor suppressor DUSP6 as potential synthetic lethal target in melanoma cell lines with BRAF V600E mutations and high DUSP6 expression.
|
28423600 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To resolve features specific to the tumor microenvironment, we searched the Ivy Glioblastoma Atlas Project (Ivy GAP) repository, which highlight DUSP1, DUSP5, and DUSP6 as the predominant family members induced within pseudopalisading and perinecrotic regions.
|
28822081 |
2017 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
CONCLUSIONS TOP2A rs471692 and DUSP6 rs2279574 SNPs were not associated with chemoradiotherapy response, whereas tumor regression, weight loss, clinical stage, and cigarette smoking were independent prognostic predictors for these Chinese patients with NSCLC.
|
28231233 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our results suggest that DUSP6 gene expression in tumour samples may be a prognostic marker in NSCLC.
|
25344212 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Interestingly, the higher staining intensities of DUSP6 were associated with the level of total ERK1/2 expression (P=0.04) and with high-risk biological features such as age (P=0.05), tumor size (P=0.01), and extrathyroidal extension (linear by linear association, P=0.02).
|
22535643 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Suppressive effects of DUSP6 in tumor formation and cancer cell mobility are seen in in vivo tumorigenicity assay and in vitro colony formation, three-dimensional Matrigel culture, cell migration and invasion chamber tests.
|
21387288 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Pharmacodynamic analysis documented reciprocal pathway inhibition associated with increased apoptosis and Bim expression in tumor tissue from the combination group, where key genes such as DUSP6 that are under MEK functional control were also modulated.
|
22271687 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
DUSP6 is a critical regulator of the ERK signaling cascade and has been implicated as a tumor suppressor.
|
21499306 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
DUSP6 inactivates extracellular signal-regulated kinase (ERK), belonging to the MAP kinase family, and can act in tumor suppressive pathways.
|
21680106 |
2011 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The methylated tumor was also methylated at the more 5' regulatory region of DUSP6.
|
20638106 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Further studies assessing the tumor suppressive role of DUSP6 and strategies aimed at modulation of its activity are warranted.
|
20097731 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Several DSPs, mainly MKPs and, unexpectedly, MTMRs, were altered following HER2-modulation in cells and 3 DSPs (DUSP6, CDC25B and MTMR11) were altered in both cells and tumors.
|
20413845 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In primary lung cancers, DUSP6 expression levels decreased as both growth activity and histological grade of the tumor increased.
|
19608870 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Restoration of chromosome 12 also suppresses growths of pancreatic cancer cells despite the recovery of expression of DUSP6; the existence of yet another tumor suppressor gene on 12q is strongly suggested.
|
16367914 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our previous study indicated that DUSP6/MKP-3/PYST1 could act as a tumor suppressor in human pancreatic cancer.
|
15824892 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The aim of this study was to elucidate the roles of DUSP6 in the pancreatic carcinogenesis through the pancreatic intraepithelial neoplasia and/or intraductal papillary-mucinous neoplasms, both of which are considered to be precursor lesions of invasive carcinoma of the pancreas, by comparing with involvements of other major tumor suppressive pathways.
|
15832194 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Mitogen-activated protein kinase phosphatase-3 is a tumor promoter target in initiated cells that express oncogenic Ras.
|
15159408 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These results show that DUSP6 exerts apparent tumor-suppressive effects in vitro and suggest that DUSP6 is a strong candidate tumor suppressor gene at 12q22 locus.
|
12759238 |
2003 |